Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the efficacy and safety of adding the once-daily glucagon-like peptide-1 receptor agonist (GLP-1RA) lixisenatide to established basal insulin therapy alone or together with metformin, in people with type 2 diabetes and elevated glycated hemoglobin (HbA1c). RESEARCH DESIGN AND METHODS: We conducted a double-blind, parallel-group, placebo-controlled trial. Patients (n = 495) with established basal insulin therapy but inadequate glycemic control were randomized to add lixisenatide 20 μg or placebo for 24 weeks. Basal insulin dosage was unchanged except to limit hypoglycemia. HbA1c reduction from baseline was the primary end point. RESULTS: Mean duration of diabetes was 12.5 years, duration of insulin use was 3.1 years, insulin dosage was 55 units/day, and baseline HbA1c was 8.4%. With lixisenatide, the placebo-corrected change of HbA1c from baseline was –0.4% (95% CI –0.6 to –0.2; P = 0.0002), and mean HbA1c at end point was 7.8%. HbA1c <7.0% (53 mmol/mol) was attained by more lixisenatide (28%) than placebo (12%; P < 0.0001) participants. Lixisenatide reduced plasma glucose levels after a standardized breakfast (placebo-corrected reduction, –3.8 mmol/L; P < 0.0001); seven-point glucose profiles showed a reduction persisting through the day. Reductions in body weight (placebo corrected, –1.3 kg; P < 0.0001) and insulin dosage (–3.7 units/day; P = 0.012) were greater with lixisenatide. Main adverse events (AEs) with lixisenatide were gastrointestinal. Symptomatic hypoglycemia was 28% for lixisenatide and 22% for placebo; 4 of 328 subjects (1.2%) had severe hypoglycemia with lixisenatide vs. 0 of 167 with placebo. CONCLUSIONS: By improving HbA1c and postprandial hyperglycemia without weight gain in type 2 diabetes with inadequate glycemic control despite stable basal insulin, lixisenatide may provide an alternative to rapid-acting insulin or other treatment options.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“At the same time, the research of GetGoal-Duo1 and GetGoal-L also found that when the basic insulin treatment was not effective, the combination of LIXI could not only significantly improve fasting blood glucose and glycosylated hemoglobin but also significantly reduce weight, with the weight dropping by 0.9 kg and 1.3 kg respectively (71).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Self-citationRiddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Global guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Rodbard, H. W., Jellinger, P. S., Davidson, J. A., Einhorn, D., Garber, A. J., Grunberger, G., Handelsman, Y., Horton, E. S., Lebovitz, H., Levy, P., et al. (2009) · Endocrine Practice · doi:10.4158/ep.15.6.540 · Cited by 942
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa075392 · Cited by 710
Three-year efficacy of complex insulin regimens in type 2 diabetes
Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., & Paul, S. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905479 · Cited by 667
Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
Self-citationNauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · cited 1×
“However, slowing of gastric emptying appears to be greater with short-acting than with longacting GLP-1RAs (13), possibly related to the observation that, with time, continuous exposure of GLP-1 leads to a reduction in its effect on gastric emptying (14).”
Research works printed but not linked: 1
- Ratner, 2009, Post-meal pharmacodynamic profile of ACE0010, a once-daily GLP-1 receptor agonst, in patients with type 2 diabetes inadequally controlled on metformin, Diabetologia, 52, S60
Cited by
Items 101–200 of 288
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
“When basic insulin treatment failed, Lixisenatide plus additional diabetic drugs caused a 0.9-kg weight reduction and a 1.3-kg improvement in HbA1c and FBG [244].”
InfluentialCavaiola, T. S., Kiriakov, Y., & Reid, T. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.11.015 · Cited by 33
The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs
Rodbard, H. W. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0103 · Cited by 30
Małyszczak, A., Przeździecka-Dołyk, J., Szydełko-Paśko, U., & Misiuk‐Hojło, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061797 · Cited by 30
Bain, S. C. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0073-z · Cited by 29
Yoon, J., Min, S. H., Ahn, C. H., Cho, Y. M., & Hahn, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-22443-1 · Cited by 31
Wysham, C., Bonadonna, R. C., Aroda, V. R., Puig‐Domingo, M., Kapitza, C., Stager, W., Yu, C. H., Niemoeller, E., Souhami, E., Bergenstal, R. M., et al. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12961 · Cited by 31
“separate injections has been shown to be more effective than basal insulin alone.(7,8) iGlarLixi, a titratable fixed-ratio combination of iGlar”
Self-citationDavies, M. J., Leiter, L. A., Guerci, B., Grunberger, G., Ampudia‐Blasco, F. J., Yu, C. H., Stager, W., Niemoeller, E., Souhami, E., & Rosenstock, J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12980 · Cited by 29
Self-citationCombining a GLP-1 Receptor Agonist and Basal Insulin: Study Evidence and Practical Considerations
Carris, N. W., Taylor, J. R., & Gums, J. G. (2014) · Drugs · doi:10.1007/s40265-014-0325-2 · Cited by 28
“5 % or less, only one of which required waiting until week 4 to resume insulin titration [24, 25].”
BackgroundMethodLixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management
McCarty, D., Coleman, M., & Boland, C. L. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017689878 · Cited by 27
“There were no significant differences in FPG; however, changes in 2-hour PPG favored lixisenatide.(23) A study similar to GetGoal-L was conducted in an Asian population on established basal insulin with or without a sulfonylurea.”
BackgroundMethodResultInfluentialKaku, K., Araki, E., Tanizawa, Y., Agner, B. F. R., Nishida, T., Ranthe, M. F., & Inagaki, N. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13856 · Cited by 32
“The complementary actions of insulin and GLP-1RAs target multiple pathophysiological defects involved in T2D, and combining both therapies together can reduce glycated haemoglobin (HbA1c) levels with lower risk of hypoglycaemia and weight gain compared with basal insulin alone.(14-17) However, this burdens patients wi…”
Wysham, C. H., Lin, J., & Kuritzky, L. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1297669 · Cited by 26
“[14]) and those which evaluated basal insulin together with an RAI (e.”
Goldenberg, R., & Berard, L. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1372118 · Cited by 27
Yang, W., Cai, X., Gao, X., Chen, Y., Chen, L., & Ji, L. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12764 · Cited by 27
Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
Zhou, Z., Yi, L., Popławska-Domaszewicz, K., Chaudhuri, К. R., Jankovic, J. J., & Tan, E. K. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107770 · Cited by 35
Ren, X., Hua, H., Wu, Y., Zhang, W., Long, X., Bai, Y., & Cheng, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-09807-0 · Cited by 38
Cai, X., Gao, X., Yang, W., & Ji, L. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1400011 · Cited by 28
“active hypoglycemic agents; (3) in type 2 diabetes participants; (4) study length longer than 12 weeks; (5) the efficacy of glucose control was the primary outcome of the study; and (6) the studies were randomized controlled trials.”
Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus
Forst, T., & Pfützner, A. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.838559 · Cited by 25
Lixisenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Scott, L. J. (2013) · BioDrugs · doi:10.1007/s40259-013-0057-y · Cited by 26
“In GetGoal-L [30], LSM changes in bodyweight were significantly greater in the lixisenatide group (LSM change -1.”
BackgroundMethodInfluentialSafety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues
Raccah, D. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1268598 · Cited by 24
Becker, R. H. A., Stechl, J., Msihid, J., & Kapitza, C. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12278 · Cited by 25
Hinnen, D., & Strong, J. L. (2018) · Diabetes Spectrum · doi:10.2337/ds17-0014 · Cited by 24
“Basal-plus and basal-bolus regimens are associated with increased risk of hypoglycemia versus basal insulin alone, as well as the potential for weight gain and a requirement for additional daily injections (11,17).”
BackgroundInfluentialNatale, P., Green, S. C., Tunnicliffe, D. J., Pellegrino, G., Toyama, T., & Strippoli, G. F. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015849.pub2 · Cited by 40
Liu, Y., He, L., Han, S., Ping, F., Li, W., Xu, L., Zhang, H., & Li, Y. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039446 · Cited by 27
Abdi, H., Azizi, F., & Amouzegar, A. (2018) · Intern J Endocrinol Metab · doi:10.5812/ijem.65600 · Cited by 24
“ticipants (76-90) assessing different outcomes of basal insulin-GLP-1 agonist combination therapy compared to other hypoglycemic agents (91) demonstrated that combined treatment results the followings: 1) greater reduc-”
InfluentialMen, P., Qu, S., Luo, W., Li, C., & Zhai, S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13871 · Cited by 29
Dar, S., Tahrani, A. A., & Piya, M. K. (2015) · Practical Diabetes · doi:10.1002/pdi.1978 · Cited by 28
Schwartz, S. S., Jellinger, P. S., & Herman, M. E. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1191955 · Cited by 24
Meier, J. J., Menge, B. A., Schenker, N., Erdmann, S., Kahle‐Stephan, M., Schliess, F., Kapitza, C., & Nauck, M. A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13935 · Cited by 24
Porcellati, F., Lucidi, P., Bolli, G. B., & Fanelli, C. G. (2015) · Diabetes & Metabolism · doi:10.1016/s1262-3636(16)30004-0 · Cited by 22
Van Gaal, L., Souhami, E., Zhou, T., & Aronson, R. (2014) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2014.03.001 · Cited by 22
Self-citationUmpierrez, G. E., Bailey, T. S., Carcia, D., Shaefer, C. F., Shubrook, J. H., & SKOLNIK, N. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12576 · Cited by 25
Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment
Hanefeld, M., Arteaga, J. M., Leiter, L. A., Marchesini, G., Nikonova, E., Shestakova, M., Stager, W., & Gómez‐Huelgas, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12986 · Cited by 22
Lisco, G., Tullio, A. D., Disoteo, O., Geronimo, V. D., Piazzolla, G., Pergola, G. D., Giagulli, V. A., Jirillo, E., Guastamacchia, E., Sabbà, C., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.920541 · Cited by 25
“GetGoal-L (45) NCT00715624 (2013) Individually randomized parallelgroup, doubleblind T2D (>1 year); HbA1c 8.”
Trujillo, J. M., & Goldman, J. D. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1962 · Cited by 22
“Finally, animal studies with GLP-1 RAs showed an increased incidence of thyroid malignancies,(61,62) but no cases were reported in the GetGoal trials.(18,20-23,27,29,30,34,36,37,39,41,45)”
Aronson, R., Umpierrez, G. E., Stager, W., & Kovatchev, B. P. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13580 · Cited by 23
“Although short- and long-acting GLP-1RAs are beneficial with regard to both FPG and PPG, Lixi has been shown to have a pronounced PPG-lowering effect and to be suitable for combination therapy with BI.(10) The different modes of action and glucose-lowering effects of the two agents combine to address both FPG and PPG…”
Self-citationLixisenatide (Adlyxin): A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes.
Leon, N., LaCoursiere, R. J., Yarosh, D., & Patel, R. S. (2017) · PubMed · Cited by 35
Trujillo, J. M., Roberts, M., DEX, T. A., Chao, J., White, J. R., & LaSalle, J. R. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13444 · Cited by 20
Handelsman, Y., Chovanes, C., DEX, T. A., Giorgino, F., SKOLNIK, N., Souhami, E., Stager, W., Niemoeller, E., & Frías, J. P. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.11.009 · Cited by 24
Self-citationDalal, M. R., Xie, L., Başer, O., & DIGENIO, A. G. (2014) · Endocrine Practice · doi:10.4158/ep14290.or · Cited by 19
“, insulin glargine, insulin detemir, neutral protamine Hagedorn [NPH] insulin) and improved glycemic control, without an accompanying increase in weight or risk of hypoglycemia (7-12).”
BackgroundResultEqual improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day
Ahrén, B., Vorokhobina, N., Souhami, E., Demil, N., Ye, J., & Aronson, R. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.05.012 · Cited by 19
Self-citationGiorgino, F., Bonadonna, R., Gentile, S., Vettor, R., & Pozzilli, P. (2016) · Diabetes/Metabolism Research Reviews · doi:10.1002/dmrr.2775 · Cited by 17
“glycemia did not differ between groups; in GetGoalDuo1, hypoglycemia was reported in a higher proportion of patients receiving lixisenatide than in those receiving insulin alone during the first 6 weeks of treatment – after this point, the incidence was similar between groups; in GetGoal-L Asia, lixisenatide was assoc…”
Yu, M. B., Brunt, K. V., Miličević, Z., Varnado, O. J., & Boye, K. S. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.10.002 · Cited by 22
Yabe, D., Ambos, A., Cariou, B., Duvnjak, L. S., Evans, M., González-Gálvez, G., Lin, J., Nikonova, E. V., de Pablos-Velasco, P. L., Yale, J., et al. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.05.018 · Cited by 18
“Treatment with lixisenatide has been shown previously to be clinically efficacious and tolerable in patients when administered as add-on to basal insulin therapy due to the complementary effects of basal insulin on FPG plus lixisenatide on PPG [13,15,26].”
Seino, Y., Yabe, D., Takami, A., Niemoeller, E., & Takagi, H. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.07.003 · Cited by 18
Self-citationEgede, L. E., Bogdanov, A., Fischer, L., Fernandes, J. D. D. R., & Kallenbach, L. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00850-w · Cited by 18
Advances in Pharmacologic Therapies for Type 2 Diabetes
Morsink, L. M., Smits, M. M., & Diamant, M. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0302-8 · Cited by 20
Witkowski, M., Wilkinson, L., Webb, N., Weids, A., Glah, D., & Vrazic, H. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0428-y · Cited by 18
“Of the eight trials considered in the base-case analysis, all trials reported data on the change from baseline in HbA1c, the proportion of patients achieving HbA1c\7% and B 6.5%, fasting plasma glucose (FPG), weight, and the incidence of nausea, vomiting, and diarrhea; only two trials (LIRAADD2BASAL [40] and SUSTAIN 5…”
Influentialde Wit, H. M., Vervoort, G., Jansen, H. J., de Galan, B. E., & Tack, C. J. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12447 · Cited by 21
Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review
Goldenberg, R. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.852078 · Cited by 18
Vedtofte, L., Knop, F. K., & Vilsbøll, T. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1288715 · Cited by 19
Ericsson, Å., Glah, D. R., Lorenzi, M. F., Jansen, J. P., & Fridhammar, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191953 · Cited by 23
Injectable Coformulations in Diabetology
Kalra, S., & Gupta, Y. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0106-2 · Cited by 17
Bonadonna, R. C., Blonde, L., Antsiferov, M. B., Berria, R., Gourdy, P., Hatunic, M., Mohan, V., & Horowitz, M. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2897 · Cited by 18
Scholz, G. H., & Fleischmann, H. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814556099 · Cited by 18
Hanefeld, M., Berria, R., Lin, J., Aronson, R., Darmon, P., Evans, M., & Gaal, L. V. (2014) · Advances in Therapy · doi:10.1007/s12325-014-0146-4 · Cited by 18
Self-citationGLP-1 receptor agonists in the treatment of Type 2 diabetes
Bo, A.-R. (2013) · Diabetes Management · doi:10.2217/dmt.13.41 · Cited by 31
Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes
Yabe, D., & Seino, Y. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.949672 · Cited by 16
“In particular, the addition of short-acting GLP-1 RAs to basal insulin is a favorable option for treatment intensification in patients with T2DM due to complementary effects on PPG and FPG, respectively, and can result in improved overall glycemic control versus basal insulin alone [112–114].”
Farngren, J., Persson, M., & Åhrén, B. (2015) · Diabetes Care · doi:10.2337/dc15-1274 · Cited by 18
“It improves glycemia with low risk for hypoglycemia both in monotherapy, in association with metformin and in combination with insulin (20-23).”
BackgroundA Plethora of GLP-1 Agonists: Decisions About What to Use and When
Samson, S. L., & Garber, A. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0823-6 · Cited by 20
Insulin Glargine/Lixisenatide: A Review in Type 2 Diabetes
Scott, L. J. (2017) · Drugs · doi:10.1007/s40265-017-0783-4 · Cited by 16
Huetson, P., Palmer, J. L., Levorsen, A., Fournier, M., Germé, M., & McLeod, E. J. (2015) · Journal of Medical Economics · doi:10.3111/13696998.2015.1038271 · Cited by 19
Novel insights into the effects of diabetes on gastric motility
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1129898 · Cited by 16
“and lixisenatide,[92] result in meaningful reductions in HbA1c, modest weight loss and, importantly, a low risk of hypoglycemia, in type 2 patients.”
Goldman, J. D., & Trujillo, J. M. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017717281 · Cited by 18
Frías, J. P., DEX, T. A., Roberts, M., & Kaplan, A. P. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0547-5 · Cited by 18
Artigas, C. F., Stokes, V. J., Tan, G. D., & Theodorakis, M. J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1052740 · Cited by 16
“GetGoal-L [15] was a double-blind, parallel-group, placebocontrolled trial; 495 patients with established basal insulin therapy were randomized to add-on lixisenatide 20 mg once daily or placebo, for 24 weeks.”
BackgroundMethodInsulin degludec/liraglutide: innovation-driven combination for advancement in diabetes therapy
Kumar, A. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.904851 · Cited by 17
“012) was observed with lixisenatide [34].”
Efficacy and Safety of GLP-1 Receptor Agonists Across the Spectrum of Type 2 Diabetes Mellitus
Leiter, L. A., & Nauck, M. A. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-103969 · Cited by 16
Linetzky, B., Curtis, B. H., Frechtel, G. D., Montenegro, R. M., Escalante-Pulido, M., Stempa, O., de Lana, J. M., & Gagliardino, J. J. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0157-1 · Cited by 16
Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials
Blonde, L., Chava, P., DEX, T. A., Lin, J., Nikonova, E. V., & Goldenberg, R. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12815 · Cited by 15
Muzurović, E. M., Dragnić, S., Medenica, S., Smolović, B., Bulajić, P., & Mikhailidis, D. P. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107619 · Cited by 17
Raccah, D., Gourdy, P., Sagnard, L., & Ceriello, A. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2548 · Cited by 14
Lixisenatide as add-on therapy to basal insulin
Evans, M., Butler, E. L., & Brown, D. X. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s45108 · Cited by 17
“The patients were randomized 2:1 to receive 20 μg of lixisenatide or a volume-matched placebo in a two-step dose increase.(51) GetGoal-L-Asia was a 24-week study assessing the efficacy and safety of a once-daily 20 μg dose of lixisenatide, against placebo, as add-on therapy to basal insulin with or without a sulfonylu…”
Raccah, D. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.11.007 · Cited by 15
Onishi, Y., Niemoeller, E., Ikeda, Y., Takagi, H., Yabe, D., & Seino, Y. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12275 · Cited by 13
Self-citationAroda, V. R., Arulandu, J. R., & Cannon, A. J. (2018) · Clinical Diabetes · doi:10.2337/cd17-0065 · Cited by 13
Chiang, C., Chang, Y., Yu, C.-C., See, X. Y., Wang, T. H., Xanthavanij, N., Song, J., Lo, S., Chiang, C.-H., Lake, L. L., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.06.020 · Cited by 15
Lind, M., Hirsch, I. B., Tuomilehto, J., Dahlqvist, S., Torffvit, O., & Pehrsson, N.-G. (2014) · Primary care diabetes · doi:10.1016/j.pcd.2014.07.010 · Cited by 13
“3%) relative HbA1c reduction in wo separate studies, respectively, when added to insulin therpy [20,21].”
Yamamoto, S., Hayashi, T., Ohara, M., Goto, S., Sato, J., Nagaike, H., Fukase, A., Sato, N., Hiromura, M., Tomoyasu, M., et al. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.03.032 · Cited by 13
McCrimmon, R. J., Falla, E., Sha, J. Z., Alsaleh, A. J. O., Lew, E., Hudson, R. D. A., Baxter, M., & PALMER, K. D. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01159-y · Cited by 15
Lixisenatide reduces glycaemic variability in insulin‐treated patients with type 2 diabetes
Umpierrez, G. E., O'Neal, D. N., DIGENIO, A. G., Goldenberg, R., Hernández-Triana, E., Lin, J., Park, C., Renard, É., & Kovatchev, B. P. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12930 · Cited by 13
Inman, T. R., Plyushko, E., Austin, N. P., & Johnson, J. L. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818763698 · Cited by 15
Osumili, B., Sapin, H., Yang, Z., Ranta, K., Paik, J. S., & Blüher, M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01728-5 · Cited by 16
“Overall, six trials [14, 32–36] and eight treatments were considered in the NMA and formed a connected network (Fig.”
van Baar, A. C. G., Meiring, S., Holleman, F., Hopkins, D., Mingrone, G., Deviere, J. M. E., Nieuwdorp, M., & Bergman, J. J. G. H. M. (2021) · Gut · doi:10.1136/gutjnl-2020-323931 · Cited by 13
Moore, M. C., Werner, U., Smith, M. S., Farmer, T. D., & Cherrington, A. D. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00354.2013 · Cited by 12
“In conclusion, the reduction in the postprandial glycemic response in the current report, combined with the promising data from clinical trials (1, 17, 39, 46, 47, 50, 56), indicates that lixisenatide could be a useful adjunct in treatment of postprandial hyperglycemia in individuals with impaired glucose tolerance or…”
Fulcher, G. R., Roberts, A., Sinha, A. K., & Proietto, J. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.03.004 · Cited by 12
Lixisenatide – A New Glucagon-like Peptide 1 Receptor Agonist in the Treatment of Type 2 Diabetes
Vidal, J. (2010) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2013.09.02.76 · Cited by 15
Vilsbøll, T., Vora, J. P., Jarlov, H., Kvist, K., & Blonde, L. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0376-0 · Cited by 12
Sheng, L., Deng, M., Li, X., Wan, H. Y., Lei, C., Prabahar, K., Hernández‐Wolters, B., & Kord‐Varkaneh, H. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111617 · Cited by 13
Monnier, L., & Colette, C. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.03.004 · Cited by 11
Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy
Davidson, J. A. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1096743 · Cited by 12
“Lixisenatide as add-on to basal insulin ± metformin ± thiazolidinedione produced a greater reduction in HbA1c and PPG levels compared with placebo [65,67].”
BackgroundResultInfluentialLin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · BMC Medicine · doi:10.1186/s12916-020-01787-4 · Cited by 12
Feng, W., Wang, W., Meng, R., Wu, G., Zhang, M., Zhang, X., Yin, H., & Zhu, D. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002290 · Cited by 11
Handelsman, Y., Muskiet, M. H. A., & Meneilly, G. S. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01126-x · Cited by 12
Pérez, M. B., Hsia, D. S., Sloan, L. A., Nell, H., Mungur, O., Hovsepian, L., Schmider, W., Spranger, R., Yang, N., & Niemoeller, E. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13343 · Cited by 14
“within the first 2 months) and then subside.(21,23,24) As this study examined lixisenatide treatment only for up to 42 days, further trials would be required to define the GI tolerability of lixisenatide over a longer period in pediatric populations.”
Self-citationFisher, M. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12380 · Cited by 11
Candido, R., Nicolucci, A., Larosa, M., Rossi, M. C., Napoli, R., Gabellieri, E., Tortato, E., Rabini, R. A., Crazzolara, D., Lucibelli, L., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.07.025 · Cited by 11
The Role of Insulin and Incretins in Neuroinflammation and Neurodegeneration
(2015) · Immunoendocrinology · doi:10.14800/ie.391 · Cited by 12
“Since GLP-1 and GIP enhance insulin signaling, the synthetic incretins (such as liraglutide and lixisenatide) and also incretin-degrading enzyme dipeptidyl peptidase-IV (DPP-IV) inhibitors (such as sitagliptin) have been used as treatment options for type 2 diabetes patients [71-73] .”
BackgroundLixisenatide: A New Option for Managing Type 2 Diabetes
Newsome, J. S. (2017) · Journal of Pharmacy Technology · doi:10.1177/8755122517711958 · Cited by 11
Fasting Versus Postprandial Hyperglycemia as a Treatment Target to Lower Elevated Hemoglobin A1C
Shaefer, C. F., Reid, T., Vlajnic, A., Zhou, R., & DIGENIO, A. G. (2015) · Endocrine Practice · doi:10.4158/ep14498.or · Cited by 9
Metadata
- Authors
- Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J.
- Affiliations
- Oregon Health & Science University (US)
- LMC Diabetes & Endocrinology (Canada) (CA)
- Newcastle University (GB)
- Inserm (FR)
- Sanofi (Germany) (DE)
- Sanofi (France) (FR)
- Sanofi (United States) (US)
- Medical City Dallas Hospital (US)
- Corresponding author
- Riddle, Matthew C.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-08-13
- Volume
- 36
- Issue
- 9
- Pages
- 2489-2496
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3747925
- OpenAlex
- W2106709036
- Cited by
- 288
- References
- 29
- Citations by year
- 2026: 6 · 2025: 11 · 2024: 9 · 2023: 8 · 2022: 7 · 2021: 11 · 2020: 11 · 2019: 12 · 2018: 32 · 2017: 41 · 2016: 36 · 2015: 44 · 2014: 39 · 2013: 20
- FWCI
- 36.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Newcastle University ePrints (Newcastle Univesity)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- lixisenatide, type 2 diabetes, basal insulin, GLP-1 receptor agonists, glycemic control, HbA1c, postprandial hyperglycemia, hypoglycemia, weight loss, insulin dose reduction, metformin, gastrointestinal adverse effects, adjunctive therapy, glycemic variability, glycemic variability index
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Aged, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Peptides
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.